Clinical Trials and Research

Cardiac MRI tissue characterization can detect early, low-burden transthyretin cardiac amyloidosis and accurately distinguish it from similar conditions, a study…

AbstractBackgroundTransthyretin amyloid cardiomyopathy (ATTR-CM) is frequently preceded by carpal tunnel syndrome (CTS). The value of age- and biopsy-guided…

This study is testing an investigational gene-editing treatment designed to reduce the production of transthyretin (TTR), a protein that causes amyloid buildup in…

This article reports a landmark first-in-world case of triple organ transplantation for advanced AL amyloidosis, using a heart, liver, and kidney recovered from a…

By Deborah Borfitz April 8, 2026 | At Cleveland Clinic, a “medically trained” AI system is patient-finding for clinical trials, eliminating…

Transthyretin is one of a small number of proteins that can misfold and aggregate to cause pathology in tissues, primarily the cardiovascular system, but other…

AbstractGlypican-4 (GPC-4), an endothelial cell surface protein, is released into the circulation in the context of ischemia, inflammation, neurohumoral activity,…

Hereditary transthyretin amyloidosis is an autosomal dominant disease caused by mutations in the TTR gene, which encodes the protein transthyretin. It is…

Swelling and fluid retention are common symptoms for individuals with transthyretin amyloid cardiomyopathy (ATTR-CM). This condition causes the heart muscle to…

In Las Vegas, Nevada, United States, DelveInsight's assessment reveals that globally, there are 10 key companies actively developing treatment therapies for AL…